NIH Funds Expand BioForce Product Development

Sep 26, 2006, 01:00 ET from BioForce Nanosciences, Inc.

    AMES, Iowa, Sept. 26 /PRNewswire/ -- The National Institutes of Health
 (NIH) National Human Genome Research Institute has approved funding of
 $400,000, with a potential for an additional $400,000 after August 31,
 2007, to BioForce Nanosciences, Inc., a wholly owned subsidiary of BioForce
 Nanosciences Holdings, Inc. (OTC Bulletin Board:   BFNH). The funding will be
 used to support the second phase of commercial development for surface
 patterning tools (SPT(TM)). SPT molecular ink cartridges are used in the
 Company's core technology, the Nano eNabler(TM) benchtop molecular printing
     "The next phase of our SPT cartridge development program focuses on the
 improvement and expansion of the capabilities and throughput of the
 devices," noted Dr. Curtis Mosher, Vice President of Research and
 Development. "SPT cartridge loading and cleaning in place are primary
 objectives of the ongoing program."
     Juntao Xu, a key BioForce research scientist on this project,
 commented, "Our ultraminiaturized SPT cartridges are manufactured using
 microfabrication techniques that allow us to readily modify the design,
 materials and processing steps to enhance tool printing performance. When
 our SPT portfolio is complete our customers should be able to print spots,
 lines and complex paths of one or many different molecules or compounds."
     Founder and CEO of BioForce Eric Henderson stated, "We were elated to
 learn of this award. NIH funding provides not only critical financial
 resources for the project but, importantly, also peer validation of the
 importance of our commercial vision."
     About BioForce Nanosciences, Inc.
     BioForce Nanosciences is a nanotechnology tools and applications
 company, providing innovative and practical products that support the
 growth of the nanotechnology industry. The Company has spent more than a
 decade on invention, research and development of patented and
 patent-pending nanotechnology products. The core technology is the Nano
 eNabler(TM) benchtop molecular printer, a portal to new opportunities in
 nanotechnology. The Nano eNabler printing system opens the door to new and
 important applications in the biomedical and life sciences markets that
 lead to improved quality of life. BioForce continues to target inventions
 that further expand the reach of its proprietary technology and expand its
 robust patent, trademark and IP portfolio.
     BioForce Nanosciences, Inc., the Practical Nanotechnology(TM) Company,
 brings inventions to the marketplace that complement existing innovations,
 licensing and acquisitions. BioForce is a wholly owned subsidiary of
 BioForce Nanosciences Holdings, Inc. (OTC Bulletin Board:   BFNH). For more
 information, visit
     This news release contains forward-looking information that may be
 affected by certain risks and uncertainties, including those risks and
 uncertainties described in the Company's most recent filings with the
 Securities and Exchange Commission. The Company's actual results could
 differ materially from such forward-looking statements. We assume no duty
 to update these statements at any future date.

SOURCE BioForce Nanosciences, Inc.